Related Experiment Video
Updated: Jan 17, 2026
Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
Pathogenesis of hepatitis C virus recurrence in the liver allograft
Geoffrey W McCaughan1, Amany Zekry
1AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. g.mccaughan@centenary.usyd.edu.au
Insights
Hepatitis C virus (HCV) infection post-transplant shows early allograft infection with high viral load. Acute hepatitis involves immune cells and cell death, differing from chronic HCV's molecular pathways.
Area of Science:
- Hepatology and Transplant Immunology
- Viral Hepatitis Pathogenesis
Background:
- Hepatitis C virus (HCV) infection in transplanted organs (allografts) presents unique challenges.
- Understanding HCV behavior in the allograft is crucial for patient outcomes.
Purpose of the Study:
- To characterize the early events and pathogenesis of Hepatitis C virus infection in liver allografts.
- To differentiate the mechanisms of cholestatic and chronic HCV hepatitis post-transplantation.
Main Methods:
- Analysis of viral kinetics and host immune responses in HCV-infected allografts.
- Comparison of molecular and cellular pathways in cholestatic versus chronic HCV hepatitis.
Main Results:
- Allograft infection occurs early with higher viral burden than in non-transplant patients.
- Acute hepatitis involves immune cell infiltration and hepatocyte apoptosis.
- Cholestatic HCV shows direct viral injury and a T helper subtype 2 (T(H)2)-like response, while chronic HCV exhibits T(H)1 inflammatory pathways.
Conclusions:
- HCV infection in allografts has distinct early phases and pathogenesis compared to non-transplant settings.
- Further research is needed to distinguish HCV infection from allograft rejection.
Abstract:
1. Hepatitis C virus (HCV) infection in the allograft occurs in the setting of greater viral burden than in nontransplantation patients. 2. Infection of the allograft occurs early (within days and possibly during the intraoperative reperfusion phase). 3. Viral burden plateaus at 1 month posttransplantation and (in the absence of cholestatic HCV) peaks at the time of acute hepatitis (1 to 4 months). 4. Acute hepatitis is associated with immune cell infiltration and hepatocyte apoptosis. 5. Cholestatic HCV seems to be a disease of direct HCV cytopathic injury in the setting of extreme virus levels, an intrahepatic T helper subtype 2 cell (T(H)2)-like response, and lack of a specific HCV-directed response. 6. Chronic hepatitic HCV seems to behave at the molecular and/or cellular level in a similar fashion to the nontransplantation setting, with activation of T(H)1 inflammatory, profibrotic, and proapoptotic pathways. This process operates at a greater viral burden than pretransplantation and leads to more progressive disease. 7. More studies are required to examine and distinguish allograft rejection in the setting of HCV infection from HCV infection alone.
More Related Videos
08:15A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
Published on: February 2, 2024
09:23Author Spotlight: Enhancing Transplantation Research Through MicroCT Angiography in Murine Models
Published on: September 22, 2023
